需要持续肾脏替代治疗患者进行物理康复与主动活动的安全性和可行性:系统评价
该系统评价检索Medline、CINAHL、PubMed、Pedro和Cochrane Library,纳入15项观察性研究,共437例需要持续肾脏替代治疗的成人ICU患者,参与某种形式的物理康复、体力活动或主动活动。在总共840次活动或移动 sessions 中,报告2例主要不良事件(需血管加压药的 hypotension 和 CRRT 管路断开,合并发生率0.24%)和13例次要不良事件(合并发生率1.55%)。干预保真度受限于高移动水平 prevalence 低,仅15.5%的事件达到或超过ICU mobility scale 5级(转移至椅子、原地踏步或离床行走,122/715份报告)。可行性报告不一致。作者结论认为早期康复和活动似乎安全且大多可行,但因纳入研究总体质量有限、报告异质性和达到的移动水平总体较低,需谨慎解读。
要点
- 在840次活动 sessions 中,仅报告2例主要不良事件(需血管加压药的 hypotension 和 CRRT 管路断开),合并发生率0.24%。
- 报告13例次要不良事件,合并发生率1.55%。
- 仅15.5%的事件达到或超过ICU mobility scale 5级(转移至椅子、原地踏步或离床行走,122/715份报告),高移动水平 prevalence 低。
- 作者结论认为早期康复和活动在需要CRRT的ICU患者中似乎安全且大多可行,但需谨慎解读。
- 可行性报告不一致,且纳入研究总体质量有限、报告异质性大,可能影响不良事件的发现。
适用人群与场景
- 纳入标准:年龄≥18岁、在ICU需要持续肾脏替代治疗、描述物理康复/主动活动/体力活动交付内容、报告安全性或可行性数据的成人患者。
- 共纳入15项观察性研究,437例需要CRRT的成人ICU患者参与某种形式的物理康复、体力活动或主动活动。
研究设计与关键结果
- 研究类型:系统评价,纳入15项观察性研究(其中7项仅关注需要CRRT患者的体力活动)。
- 样本量:437例需要CRRT的成人ICU患者,共840次个体活动或移动 sessions。
- 主要结局安全性:2例主要不良事件(需血管加压药的 hypotension 和 CRRT 管路断开),合并发生率0.24%;13例次要不良事件,合并发生率1.55%。
- 干预保真度:仅15.5%的事件达到或超过ICU mobility scale 5级(转移至椅子、原地踏步或离床行走,122/715份报告)。
- 可行性:提供这些干预和/或CRRT特定交付内容的可行性报告不一致。
证据类型、等级与局限
- 证据类型:系统评价,纳入15项观察性研究。
- 局限:纳入研究总体质量有限、报告异质性、达到的移动水平总体较低,可能妨碍不良事件的发生或检测;可行性报告不一致。
对床旁实践的改变
- 作者认为,在需要CRRT的ICU患者中,早期康复和活动(特别是床内及床旁活动)似乎安全且大多可行。
- 作者指出,由于纳入研究总体质量有限、报告异质性和达到的移动水平总体较低,需谨慎解读这些数据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the safety and feasibility of physical rehabilitation and active mobilization in patients requiring continuous renal replacement therapy in the ICU.
DATA SOURCES: Medline, CINAHL, PubMed, Pedro, and Cochrane Library were used to extract articles focused on physical activity and mobility in this population.
STUDY SELECTION: Research articles were included in this review if 1) included adult patients greater than or equal to 18 years old requiring continuous renal replacement therapy located in the ICU; 2) described physical rehabilitation, active mobilization, or physical activity deliverables; 3) reported data on patient safety and/or feasibility. The primary outcome was safety, defined as number of adverse events per total number of sessions.
DATA EXTRACTION: Five-hundred seven articles were evaluated based on title and abstract with reviewers selecting 46 to assess by full text. Fifteen observational studies were included for final analysis with seven studies focused solely on physical activity in patients requiring continuous renal replacement therapy.
DATA SYNTHESIS: Four-hundred thirty-seven adult ICU patients requiring continuous renal replacement therapy participated in some form of physical rehabilitation, physical activity, or active mobilization. Two major adverse events (hypotension event requiring vasopressor and continuous renal replacement therapy tube disconnection, pooled occurrence rate 0.24%) and 13 minor adverse events (pooled occurrence rate 1.55%) were reported during a total of 840 individual mobility or activity sessions. Intervention fidelity was limited by a low prevalence of higher mobility with only 15.5% of incidences occurring at or above level 5 of ICU Mobility Scale (transfer to chair, marching in place or ambulation away from bed, 122/715 reports). Feasibility in the provision of these interventions and/or continuous renal replacement therapy-specific deliverables was inconsistently reported.
CONCLUSIONS: Early rehabilitation and mobilization, specifically activity in and near the hospital bed, appears safe and mostly feasible in ICU patients requiring continuous renal replacement therapy. A cautious interpretation of these data is necessary due to limited aggregate quality of included studies, heterogeneous reporting, and overall low achieved levels of mobility potentially precluding the occurrence or detection of adverse events.
参考来源
- Mayer KP, Joseph-Isang E, Robinson LE, et al. Safety and Feasibility of Physical Rehabilitation and Active Mobilization in Patients Requiring Continuous Renal Replacement Therapy: A Systematic Review. Crit Care Med. 2020. PMID: 33001619. doi:10.1097/CCM.0000000000004526
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。